Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer

This study has been completed.

Sponsor:

Collaborator:

Novartis

Information provided by:

Stanford University

ClinicalTrials.gov Identifier:

NCT00226954

First received: September 13, 2005

Last updated: July 27, 2009

Last verified: July 2009

History of Changes

Purpose

Primary:

To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently.

Secondary Objectives:

To describe the safety and tolerability at this dose and schedule

Condition	Intervention	Phase
Urologic Neoplasms	Drug: zoledronic acid	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer

Resource links provided by NLM:

MedlinePlus related topics: Cancer Prostate Cancer

Drug Information available for: Zoledronic acid

U.S. FDA Resources

Further study details as provided by Stanford University:

Primary Outcome Measures:

To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently.

Secondary Outcome Measures:

To describe the safety and tolerability at this dose and schedule


Estimated Enrollment:	30
Study Start Date:	March 2003
Study Completion Date:	February 2009
Primary Completion Date:	November 2007 (Final data collection date for primary outcome measure)

Eligibility


Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:Patients: Who are 18 years of age and older Who have histologically documented adenocarcinoma of prostate Who are currently receiving LHRH agonists KPS greater than 80%Life expectancy greater than 6 months Provide written consent pursuant to regulatory requirements prior to initiation of study procedure

Exclusion Criteria:Exclusion Criteria: Patients: Any patient requiring continuous LHRH Any patient who has had an orchiectomy Any patient with painful bone metastases Who have received chemotherapy for prostate cancer Who have a abnormal serum creatine >2.5 Receiving any investigational drug within the last 28 days Severe uncontrolled infection, diabetes, cardiac disease Patients with fragility fractures, hyperparathyroidism, Pagets renal osteodystrophy will be excluded History of non compliance to medical regimens or unwillingness to return for medical visits

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00226954

Locations


United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305

Sponsors and Collaborators

Stanford University

Novartis

Investigators


Principal Investigator:	Dr. Sandy Srinivas	Stanford University

More Information

No publications provided


Responsible Party:	Dr. Sandy Srinivas, Principal Investigator, Stanford University School of Medicine
ClinicalTrials.gov Identifier:	NCT00226954 History of Changes
Other Study ID Numbers:	PROS0001, 78869, PROS0001
Study First Received:	September 13, 2005
Last Updated:	July 27, 2009
Health Authority:	United States: Institutional Review Board

Additional relevant MeSH terms:


Urologic Neoplasms Neoplasms Neoplasms by Site Urogenital Neoplasms	Zoledronic acid Bone Density Conservation Agents Pharmacologic Actions Physiological Effects of Drugs

ClinicalTrials.gov processed this record on March 01, 2015

To Top